Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among the treatments recommended for high-risk ambulatory persons with coronavirus 2019 (COVID-19). Here, we study viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial (ClinicalTrials.gov: NCT04518410). Viral load by qPCR and viral culture are performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAbs results in rapid clearance of culturable virus. One day after treatment, 0 of 28 (0%) participants receiving mAbs and 16 of 39 (41%) receiving placebo still have culturable virus (p < 0.0001). Recrudescence of culturable virus is...
An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibo...
COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeuti...
The occurrence of SARS-CoV-2 virus at the end of 2019 and the quick progress of the infection to pan...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among ...
SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. ...
International audienceObjectives: To evaluate the impact of neutralizing monoclonal antibody (mAb) t...
BackgroundSince the beginning of the COVID-19 pandemic, patients with Inborn Errors of Immunity have...
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the avai...
The clinical impact of anti-spike monoclonal antibodies (mAb) in Coronavirus Disease 2019 (COVID-19)...
SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. ...
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infec...
Background Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells o...
Despite the widespread use of SARS-CoV-2-specific monoclonal antibody (mAb) therapy for the treatmen...
Background Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells o...
An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibo...
COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeuti...
The occurrence of SARS-CoV-2 virus at the end of 2019 and the quick progress of the infection to pan...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among ...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among ...
SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. ...
International audienceObjectives: To evaluate the impact of neutralizing monoclonal antibody (mAb) t...
BackgroundSince the beginning of the COVID-19 pandemic, patients with Inborn Errors of Immunity have...
As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the avai...
The clinical impact of anti-spike monoclonal antibodies (mAb) in Coronavirus Disease 2019 (COVID-19)...
SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. ...
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infec...
Background Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells o...
Despite the widespread use of SARS-CoV-2-specific monoclonal antibody (mAb) therapy for the treatmen...
Background Monoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells o...
An Emergency Use Authorization was issued in the United States and in Europe for a monoclonal antibo...
COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeuti...
The occurrence of SARS-CoV-2 virus at the end of 2019 and the quick progress of the infection to pan...